SOLAR-PROMOTION-GMBH
4.6.2024 14:50:36 CEST | Business Wire | Press release
Battery storage is booming. According to a study by Frontier Economics, the volume of grid-connected storage in Germany alone could increase to 60 gigawatts (GW) or 271 gigawatt-hours (GWh) by 2050. This is forty times the current storage capacity. Similar dynamics in cost reduction and installation speed are expected as seen with photovoltaics (PV) in recent years. Soon, battery storage will fundamentally change energy supply. The latest technologies, trends, and market developments will be showcased at ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems. It will take place from June 19 to 21 as part of The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry, in Munich. Around 3,000 exhibitors and over 115,000 visitors from around the world are expected in 19 exhibition halls and an outdoor area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604806032/en/
Innovations in the field of large-scale storage can be seen at this year’s ees Europe. (Photo: Business Wire)
The growth of grid-connected storage brings enormous advantages to the energy system and offers economic benefits. The expansion of large-scale storage can significantly reduce the need for new gas power plant investments in Germany by up to 9 GW. This expansion also contributes significantly to reducing CO2 emissions. The key point: this growth is purely market-driven and does not rely on government subsidies.
Short-term storage enables system transformation
Battery storage increasingly assumes critical roles in ensuring a reliable power supply and stabilizing power grids. Large battery storage systems ensure voltage control, provide immediate reserve capacity, and facilitate black start capability, playing a part in congestion management. They can balance fluctuations in the grid within seconds and store energy for hours or days. The black start capability of storage systems is crucial in emergencies.
Moreover, storage systems can mitigate the effects of delayed grid expansion. They help optimize the utilization of the limited grid infrastructure, allowing more facilities to be connected. This enables more capacity and additional PV installations despite limited grid connection capacity. Another benefit: battery storage increases the market value of renewable energy. Green electricity can be stored when market prices are low and fed into the grid when demand is high and electricity prices are correspondingly high.
International storage revolution
Worldwide, exponential growth in battery storage is evident. Experts predict that global production capacity will rise to 500 GWh per year by 2025. In markets such as Australia, the USA, and India, tenders for new wind or solar capacities have been coupled with storage for years. In Germany, the speed of expansion and the installed storage capacity are still modest. However, this year, battery storage systems in Germany will surpass pumped storage systems in installed capacity for the first time.
Setting the right framework
To make stationary storage of all sizes attractive, a favorable market environment and simple regulations are needed. Market-driven expansion must continue to be enabled and improved. Modern framework conditions for battery storage should be set through reforms in grid fees, flexible electricity tariffs, or the introduction of contracts for difference.
ees Europe
Every year, ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems, provides a networking opportunity for the industry’s key players – all under the motto “Innovating Energy Storage”. It focuses on the latest technologies, trends and market developments. ees Europe will take place from June 19–21, 2024 as part of The smarter E Europe at Messe München.
For more information: www.ees-europe.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604806032/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom